

CLAIMS

1. Use of IL-21 for the manufacture of a medicament for the treatment of diseases or conditions where eosinophils are involved in a protective response in a subject in need thereof.

5

2. Use of IL-21 for the manufacture of a medicament for the treatment of allergic conditions in a subject in need thereof.

10 3. Use according to claim 1 and claim 2 wherein the allergic condition are asthma, allergic rhinitis or allergic diseases in the skin.

4. Use of IL-21 for the manufacture of a medicament for the treatment of parasitic diseases in a subject in need thereof.

15 5. Use according to claim 4, where the parasitic disease is a helminthic infection.

6. Use of an IL-21 polypeptide having a sequence identity to the polypeptide of SEQ ID No: 2, or to residues 30 to 162 of SEQ ID No: 2, of at least 70% for the manufacture of a medicament for the treatment of diseases or conditions where eosinophils are involved in a protective response in a subject in need thereof.

20 7. Use of an IL-21 polypeptide having a sequence identity to the polypeptide of SEQ ID No: 2, or to residues 30 to 162 of SEQ ID No: 2, of at least 70% for the manufacture of a medicament for the treatment of allergic conditions in a subject in need thereof.

25

8. Use according to claim 7 wherein the allergic conditions are asthma, allergic rhinitis or allergic diseases in the skin.

9. Use of an IL-21 polypeptide having a sequence identity to the polypeptide of SEQ ID No: 30 2, or to residues 30 to 162 of SEQ ID No: 2, of at least 70% for the manufacture of a medicament for the treatment of parasitic diseases in a subject in need thereof.

10. Use according to claim 9, where the parasitic disease is a helminthic infection.

11. Use according to any of claims 6 to 10, wherein the IL-21 polypeptide has a sequence identity to the polypeptide of SEQ ID No: 2, or to residues 30 to 162 of SEQ ID No: 2, of at least 80%.

5 12. Use according to claim 11, wherein the IL-21 polypeptide has a sequence identity to the polypeptide of SEQ ID No: 2, or to residues 30 to 162 of SEQ ID No: 2, of at least 90%.

13. Use according to claim 12, wherein the IL-21 polypeptide has a sequence identity to the polypeptide of SEQ ID No: 2, or to residues 30 to 162 of SEQ ID No: 2, of at least 95%.